Skip to main content

Nutraceutical supplementation based on colostrum for prevention of osteoporosis

Objective

Osteoporosis constitutes a major public health concern. The economic burden of osteoporotic fractures in EU is expected to increase 25% by 2025 compared to 2010. These estimates may indicate an inefficiency of current drugs for osteoporosis. Actually, the use of pharmacological agents for osteoporosis has been decreasing in EU, probably due to the reported side effects. Therefore, there is a need for innovative agents to reduce the burden of osteoporosis. Colostrum is a promising agent against bone loss since it has natural constituents that are directly involved in bone metabolism. As a nutraceutical, colostrum confers an advantage over pharmacological drugs since it can avoid side effects. However, the possibility of its use as a nutraceutical agent for osteoporosis have only received attention within the scientific community. The knowledge produced on the effects of colostrum on bone metabolism has not yet been transferred to the market because academic institutions lack on expertise to create a new product. On the other hand, industry has knowledge on product development, but lack expertise on research skills. In accordance, what hinders the creation of an innovative product based on colostrum for prevention of osteoporosis is the absence of an intersectorial collaboration. As consequence, there is a clearly gap between research on the matter and its application. COLOSTEO aims to fill in this gap by creating an intersectorial collaboration to exchange knowledge and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis. This aim will be achieved by bridging two academic with two industrial institutions that through intersectorial secondments will exchange knowledge, ideas and expertise towards the creation of an innovative nutraceutical product based on colostrum to prevent osteoporosis.

Coordinator

PANEPISTIMIO THESSALIAS
Net EU contribution
€ 207 000,00
Address
Argonafton Filellinon
38221 Volos
Greece

See on map

Region
Μαγνησία Θεσσαλία Κεντρική Ελλάδα
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (4)

UNIVERSIDADE DO PORTO
Portugal
Net EU contribution
€ 207 000,00
Address
Praca Gomes Teixeira
4099-002 Porto

See on map

Region
Continente Norte Área Metropolitana do Porto
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
CENTRO DE ESTUDIOS SUPERIORES DE LA INDUSTRIA FARMACEUTICA SA

Participation ended

Spain
Net EU contribution
€ 0,00
Address
Calle Del General Alvarez De Castro 41
28020 Madrid
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
CHRISTOS PAPADOPOULOS & SIA OE
Greece
Net EU contribution
€ 207 000,00
Address
Kitrous Episkopou 71
431 00 Karditsa

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Καρδίτσα Θεσσαλία Κεντρική Ελλάδα
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
SALURIS NETWORK SL
Spain
Net EU contribution
€ 207 000,00
Address
Calle Arroyo Fontarron 53
28030 Madrid

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00